ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1556100
This article is part of the Research TopicInnovative Value-Based Medicine: Lessons from China's Healthcare EvolutionView all 5 articles
Cost-effectiveness analysis of Toripalimab regimen for extensive-stage small-cell lung cancer in China and America
Provisionally accepted
- 1Department of Pharmacy, Chengdu Second People’s Hospital, Chengdu, Sichuan Province, China
- 2Department of Pharmacy, First Affiliated Hospital of Xiamen University, Xiamen, Fujian Province, China
- 3Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, Nanjing, China
- 4Department of Pharmacy, Nanjing Drum Tower Hospital, Nanjing, Jiangsu Province, China
- 5School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objectives: Toripalimab combined with chemotherapy is a clinically valuable and important regimen in the treatment of extensive-stage small-cell lung cancer (ES-SCLC). However, there are no studies on the cost-effectiveness of this regimen, so this study was designed to evaluate the cost-effectiveness of Toripalimab regimen for the treatment of ES-SCLC from the perspectives of the Chinese health system and the U.S.health system, respectively.Methods: A partitioned survival model was developed to simulate the clinical progression and cost consumption of ES-SCLC using the results of the EXTENTORCH study as a source of survival data and incorporating direct medical costs. Model output metrics included incremental cost-effectiveness ratio (ICER), quality-adjusted lifeyears (QALYs), incremental QALYs, total costs, and incremental costs. The costeffectiveness of the Toripalimab scheme was judged by comparing the ICER with the willingness to pay (WTP). The robustness of the model was verified by sensitivity analysis and scenario analysis.Resulys: The results of the basic analysis showed that from the perspective of the Chinese health system, the Toripalimab group gained 0.18 QALYs more at a cost of $5,204, with an ICER of $29,139/QALY (
Keywords: cost-effectiveness analysis, extensive-stage small-cell lung cancer, Toripalimab, chemotherapy, EXTENTORCH study
Received: 06 Jan 2025; Accepted: 28 Apr 2025.
Copyright: © 2025 Yang, Chen, Zhou, Wang and Long. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Hao Wang, Department of Pharmacy, Nanjing Drum Tower Hospital, Nanjing, 210008, Jiangsu Province, China
Yunchun Long, School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.